Further analysis of the TMEscore—a gastric cancer immune efficacy prediction score developed by our team—showed that patients with the “ CD8+ T Cell Exhaustion Dominant “ type had higher TMEscores, indicating better immune therapy responses, whereas those with the “Immunosuppressive Barrier with CD8+ T Cell Exhaustion “ had the lowest TMEscores, suggesting immune resistance (Figure 7C; Supplementary Figure S6C). The gene discussed is CD8A; the disease is gastric cancer.